Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children. Howard G, Weiner D, Bar-Or I, Levine A, et al. Eur J Gastroenterol Hepatol 2022;34:372-374.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Howard G, Weiner D, Bar-Or I, Levine A, et al. Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children. Eur J Gastroenterol Hepatol 2022;34:372-374.
PMID: 34034281